Internal Medicine, Medical Oncology · Aurora, CO
NPI
1336482769
Since 2013
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1665 Aurora Ct
Aurora, CO, 80045
Phone (720) 848-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$50K
509 services
Medicare patients, 2024
143
Average age 72
Drug cost, 2024
$2.9M
674 prescriptions
Company payments, 2025
$30K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tejas Patil was code 99215 (office e&m - established), 292 times for 97 patients. In total Tejas Patil billed 509 services in 12 codes, and Medicare paid $50K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 292 | 97 | $109.14 | $32K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 59 | 34 | $13.06 | $771 |
| 99215 Office E&M - Established | Office | 50 | 28 | $139.63 | $6,982 |
| 99205 Office E&M - New | Facility | 32 | 32 | $143.32 | $4,586 |
| 99233 Hospital E&M - Subsequent | Facility | 12 | 12 | $93.64 | $1,124 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 12 | 11 | $24.75 | $297 |
By year: 2022 $43K for 371 services; 2023 $39K for 351 services; 2024 $50K for 509 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tejas Patil prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 76 prescriptions and refills. In total Tejas Patil wrote 674 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 76 | 76 | Under 11 | $1.1M |
| Prochlorperazine Maleate Generic | 46 | 46 | 28 | $574 |
| Dexamethasone Generic | 46 | 46 | 21 | $363 |
| Ondansetron Hcl Generic | 44 | 44 | 28 | $310 |
| Eliquis Apixaban | 33 | 63 | Under 11 | $40K |
| Oxycodone Hcl Generic | 31 | 31 | Under 11 | $689 |
| Alecensa Alectinib Hcl | 29 | 29 | Under 11 | $499K |
| Xarelto Rivaroxaban | 21 | 41 | Under 11 | $23K |
| Levothyroxine Sodium Generic | 20 | 42 | Under 11 | $117 |
| Retevmo Selpercatinib | 19 | 19 | Under 11 | $355K |
| Levetiracetam Generic | 14 | 20 | Under 11 | $716 |
| Trazodone Hcl Generic | 14 | 34 | Under 11 | $132 |
| Morphine Sulfate Er Morphine Sulfate | 13 | 13 | Under 11 | $461 |
| Lorazepam Generic | 12 | 12 | Under 11 | $22.9 |
| Gabapentin Generic | 12 | 20 | Under 11 | $90.72 |
Brand drugs: 262 claims; generic drugs: 412 claims; opioid claims: 53.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tejas Patil $30K ($30K in general payments such as food, travel and fees and $557 for research) from 12 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $8,463.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 6 | $8,463 |
| Partner Therapeutics, Inc. | 6 | $5,796 |
| Eli Lilly and Company LLY | 3 | $4,438 |
| Janssen Scientific Affairs, LLC JNJ | 3 | $4,262 |
| Janssen Biotech, Inc. JNJ | 3 | $2,497 |
| EMD Serono, Inc. MRK.DE | 1 | $2,115 |
| Janssen Global Services, LLC JNJ | 3 | $1,854 |
| F. Hoffmann-La Roche AG ROG.SW | 2 | $557 |
| Genentech, Inc. ROG.SW | 1 | $76.27 |
| Gilead Sciences, Inc. GILD | 1 | $54.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.